BioCentury
ARTICLE | Company News

Axerion Therapeutics, AstraZeneca deal

May 7, 2012 7:00 AM UTC

Axerion granted AstraZeneca's MedImmune LLC biologics unit exclusive rights to develop and commercialize a preclinical mAb for Alzheimer's disease that inhibits the interaction between prion protein...